Skip to Content
Merck
CN

EHU019431

MISSION® esiRNA

targeting human EEA1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


description

Powered by Eupheria Biotech

Quality Level

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CACAAGACCGTGTCCTTTCCCTAGAAACTAGTGTCAATGAATTAAATAGTCAATTAAATGAAAGCAAGGAGAAGGTCTCCCAGCTTGACATACAGATTAAAGCCAAAACCGAACTATTACTATCAGCAGAAGCAGCAAAAACTGCTCAAAGAGCTGATCTTCAGAATCATTTGGACACAGCTCAAAATGCATTACAAGATAAACAGCAGGAGTTAAATAAGATTACTACTCAGTTGGATCAGGTCACTGCAAAGTTACAAGACAAGCAAGAACATTGCAGTCAGCTGGAAAGTCATCTTAAAGAATATAAAGAGAAATACCTCTCTTTAGAACAGAAAACCGAAGAGCTAGAAGGTCAAATTAAGAAACTAGAAGCTGATAGTCTTGAAGTTAAAGCAAGCAAGGAGCAGGCTTTGCAAGATCT

Ensembl | human accession no.

NCBI accession no.

shipped in

ambient

storage temp.

−20°C

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany


Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Rossella Bengalli et al.
BioMed research international, 2013, 158093-158093 (2013-03-20)
Particulate matter (PM) exposure is related to pulmonary and cardiovascular diseases, with increased inflammatory status. The release of the proinflammatory interleukin- (IL-) 1β, is controlled by a dual pathway, the formation of inactive pro-IL-1β, through Toll-like receptors (TLRs) activation, and
Sandhya Xavier et al.
PloS one, 5(9), e12995-e12995 (2010-10-05)
BAMBI (BMP and Activin Membrane Bound Inhibitor) is considered to influence TGFβ and Wnt signaling, and thereby fibrosis. Surprisingly data on cell type-specific expression of BAMBI are not available. We therefore examined the localization, gene regulation, and protein turnover of



Global Trade Item Number

SKUGTIN
EHU019431-20UG04061828567263
EHU019431-50UG04061831371017